Fig. 5

Improved Therapeutic Consistency and Efficacy of CD317⁺ MSCs. The MSCs were expanded with different batches of media or from different donors A PBMC proliferation assay after coculture with MSCs (n = 3). B Percentage of CD317⁺ MSCs (n = 3). C Correlation analysis between lymphocytes proliferation suppressed by MSCs and the percentage of CD317⁺ MSCs within MSCs. D Correlation analysis between histology score in IBD mice treated with MSCs and the percentage of CD317⁺ MSCs within MSCs. E Correlation analysis between serum levels of TNF-α in IBD mice treated with MSCs and the percentage of CD317⁺ MSCs within MSCs. F PBMC proliferation assay after coculture with CD317⁺ MSCs (n = 3). F PBMC proliferation assay after coculture with CD317⁺ MSCs (n = 3). G Histology score in IBD mice treated with CD317⁺ MSCs (n = 8). H Serum levels of TNF-α in IBD mice treated CD317⁺ MSCs (n = 8). *Indicates P < 0.05